Dose escalation and expansion cohorts in patients with advanced breast cancer in a Phase I study of the CDK7-inhibitor samuraciclib

Samuraciclib is a selective oral CDK7-inhibitor. A multi-modular, open-label Phase I study to evaluate safety and tolerability of samuraciclib in patients with advanced malignancies was designed (ClinicalTrials.gov: NCT03363893). Here we report results from dose escalation and 2 expansion cohorts: M...

Full description

Saved in:

Bibliographic Details
Published in:	Nature communications Vol. 14; no. 1; pp. 4444 - 10
Main Authors:	Coombes, R. C., Howell, Sacha, Lord, Simon R., Kenny, Laura, Mansi, Janine, Mitri, Zahi, Palmieri, Carlo, Chap, Linnea I., Richards, Paul, Gradishar, William, Sardesai, Sagar, Melear, Jason, O’Shaughnessy, Joyce, Ward, Patrick, Chalasani, Pavani, Arkenau, Tobias, Baird, Richard D., Jeselsohn, Rinath, Ali, Simak, Clack, Glen, Bahl, Ashwani, McIntosh, Stuart, Krebs, Matthew G.
Format:	Journal Article
Language:	English
Published:	London Nature Publishing Group UK 24.07.2023 Nature Publishing Group Nature Portfolio
Subjects:	13/95 38/23 631/67/1059/153 692/308/153 692/4028/67/1347 Administration, Oral Anticancer properties Antitumor agents Biopsy Breast cancer Cancer therapies Cyclin-dependent kinase 4 Cyclin-Dependent Kinase Inhibitor Proteins Cyclin-Dependent Kinases Diarrhea Disease control DNA-directed RNA polymerase Enzyme Inhibitors ErbB-2 protein Fulvestrant Humanities and Social Sciences Humans Inhibitors Lymphocytes Malignancy Modules multidisciplinary Oral administration Patients Pharmacodynamics Pharmacokinetics RNA polymerase RNA polymerase II Safety Science Science (multidisciplinary) Solid tumors Substrates Triple Negative Breast Neoplasms Tumors Vomiting
ISSN:	2041-1723, 2041-1723
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!